Immune Checkpoint Inhibitor Therapy Triggers Autoimmune Cerebellar Ataxia with Anti-P/Q-type VGCC Antibody and Anti-mGluR5 Antibodies: A Case Report
Year: 2026
Type: article
Study design: Case Report
Abstract: Autoimmune cerebellar ataxia (ACA) is an immune-mediated cerebellar syndrome that is often associated with specific autoantibodies. We report a case of a 61-year-old man with small cell lung cancer who developed subacute progressive cerebellar ataxia after durvalumab therapy. Anti-P/Q-type voltage-gated calcium channel (VGCC) and anti-metabotropic glutamate receptor 5 (mGluR5) antibodies were detected. The patient improved substantially with early immunotherapy and the discontinuation of immune checkpoint inhibitor (ICIs) therapy. In this case, anti-VGCC antibodies may have contributed to the pathophysiology. However, anti-mGluR5 antibodies were also detected. The relationship between ACA and ICIs therapy remains unclear, and additional cases are needed.
Source: Internal Medicine
Authors: Shuntaro Nakamura, Kazuki Yamada, Hiroaki Yaguchi, Akihiko Kudo, Shintaro Fujii, Taichi Nomura, Shoki Sato, Taishi Iwanami, Kaiki Kawakita, Hanko Sato, Keita Majima, Kei Oiwa, Kosuke Iwami, Daiki Tanaka, Katsuki Eguchi, Hisashi Uwatoko, Shinichi Shirai, Ikuko Takahashi-Iwata, Masaaki Matsushima, Doppo Fukui, Megumi Furuta, Fumitaka Shimizu, Keiko Tanaka, Satoshi Konno, Ichiro Yabe
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7214576246